npj Parkinsons Disease

Papers
(The H4-Index of npj Parkinsons Disease is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease292
Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome173
Investigating the ageing-Parkinson’s disease nexus: standardisation of in vitro models and techniques by the PD-AGE network136
Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease125
Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson’s disease124
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease121
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI117
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions113
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology107
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease103
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease101
Differences in brain aging between sexes in Parkinson’s disease97
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease96
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances90
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease90
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders88
Biological aging predicts mortality in Parkinson’s patients: evidence from UK Biobank84
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective84
Physiotherapy interventions for balance impairments in Parkinson’s disease: evidence from a systematic review and dose-response meta-analysis81
Subthalamic nucleus in patients with Parkinson’s disease encodes changes and magnitude of applied force80
Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein78
Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson’s disease78
Association between functional gastrointestinal disorders and Parkinson’s disease in a prospective cohort study77
Advanced brain aging in Parkinson’s disease with cognitive impairment76
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease75
The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model70
Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease69
Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population69
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset69
Machine learning prediction of discharge destination in patients with Parkinson’s disease; a nationwide cohort study69
Targeting the hypothalamic a11 nucleus to treat parkinsonian-like nociceptive impairments64
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings64
Video-based machine learning models for predicting deep brain stimulation outcomes in Parkinson’s disease patients62
EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease60
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies60
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD59
Direct disassembly of α-syn preformed fibrils into α-syn monomers by an all-D-peptide58
The pattern of fMRI activation with STN DBS reveals symptom-specific networks58
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease58
Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research57
The experience of Anxiety for people with Parkinson’s disease57
Impaired migratory phenotype of CD4+ T cells in Parkinson’s disease56
Association of the number of minor hallucinations and well-structured visual hallucinations in Parkinson’s disease56
Lrrk2 G2019S mutation incites increased cell-intrinsic neutrophil effector functions and intestinal inflammation in a model of infectious colitis54
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia54
Cortical macro- and microstructural changes in isolated rapid eye movement sleep behavior disorder53
Synuclein phosphorylation: pathogenic or physiologic?53
Enrichment of gut-derived metabolites in a Parkinson’s disease subtype with REM sleep behavior disorder53
C/EBPβ/AEP is age-dependently activated in Parkinson’s disease and mediates α-synuclein in the gut and brain52
Antiviral innate immunity induces alpha synuclein phosphorylation at serine129 in neurons independent of aggregation52
Resting and action tremor in Parkinson’s disease: pathophysiological insights from long-term STN-DBS52
0.15953397750854